Focused On-demand Library for V-type proton ATPase 116 kDa subunit a 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y487

UPID:

VPP2_HUMAN

Alternative names:

Lysosomal H(+)-transporting ATPase V0 subunit a 2; TJ6; Vacuolar proton translocating ATPase 116 kDa subunit a isoform 2

Alternative UPACC:

Q9Y487; A8K026; Q6NUM0

Background:

V-type proton ATPase 116 kDa subunit a 2, also known as Lysosomal H(+)-transporting ATPase V0 subunit a 2, plays a crucial role in acidifying intracellular compartments and the extracellular environment. This protein is a key component of the V-ATPase complex, essential for pH regulation and glycosylation processes. It also influences iron homeostasis and cellular response to oxygen levels, impacting HIF1A stability.

Therapeutic significance:

Linked to Cutis laxa, autosomal recessive, 2A, and Wrinkly skin syndrome, V-type proton ATPase 116 kDa subunit a 2's dysfunction elucidates its potential in targeted therapy for these genetic disorders. Understanding its role could pave the way for innovative treatments, emphasizing the importance of research in this area.